GC Pharma (formerly known as Green Cross Corporation), a South Korean biopharmaceutical company, announced the establishment of Curevo Inc. The newly established Seattle-based company’s goal is to support GC Pharma’s vaccine development activities.
GC Pharma builds a strategic collaboration and partnership with global health organizations IDRI (Infectious Disease Research Institute, Seattle, USA) and MIBR (Mogam Institute for Biomedical Research, Seoul, South Korea) to form the new company.
Curevo represents an important next step in GC Pharma’s vaccine business. The new company will bring together GC Pharma’s commercial scale vaccine development expertise and deep understanding of protein science with IDRI and MIBR’s world class scientific expertise in vaccine, adjuvant and formulation development. Initial work will centre on advancing an innovative vaccine candidate against shingles to clinical stage.
GC Pharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018.